How small- and mid-cap and pre-IPO healthcare companies can integrate non-dilutive federal funding into their capital stack to reach critical milestones and optimize capital and investor relations strategies
Written by: Vivian Cervantes, Managing Director, Head of Healthcare, Alliance Advisors IR
For small- and mid-cap and pre-IPO healthcare companies, capital strategy plays a central role in advancing critical milestones, de-risking innovation, and creating enterprise value. Clinical development, regulatory requirements, market access and commercialization all compete for limited resources. Equity, debt, revenue and strategic partnerships remain central to that equation, but non-dilutive federal funding may represent another important and often underutilized source of capital.
Federal funding should not be viewed simply as an opportunity to secure a grant. When incorporated into a broader development and capital strategy, federal engagement can help companies advance critical milestones, generate external validation and strengthen their positioning with investors and strategic partners.
This was the focus of a recent discussion hosted by Alliance Advisors IR with Converge Public Strategies, a government and public affairs advisory firm with extensive experience navigating federal agencies, policy and funding opportunities. Together, we explored how healthcare companies can align federal funding, regulatory planning and investor communications to support innovation and long-term enterprise value creation. The discussion reinforced three central ideas: federal funding should be considered as a strategic source of non-dilutive capital; companies should build a coordinated funding pathway and coalition rather than pursue a grant in isolation; and each federal milestone should be connected to the broader objective of reducing risk, advancing innovation and creating value.
Below are five considerations for management teams evaluating where federal engagement may fit within their broader strategy.
1. Build a Funding Pathway, Not a Grant Strategy
Federal funding should be considered across the full development lifecycle, from discovery and proof of concept through validation, advanced development, regulatory progress, and commercialization. Different programs may become relevant at different stages. A single award is therefore not the strategy; the strategy is understanding where federal capital or support may help move an asset toward its next meaningful value inflection point.
For smaller public and pre-IPO companies, this distinction is especially important. The amount awarded matters, but so does what the funding enables: additional data, scientific validation, manufacturing readiness, regulatory clarity, market access, or commercial readiness. Those outcomes can strengthen the company’s position for future financing, partnerships, or other strategic transactions.
2. Start with mission alignment
The first question should not be, ‘Where can we apply?,’ but instead, ‘Which federal mission does our technology help accomplish?’ The federal healthcare ecosystem includes agencies and programs with different mandates, priorities, eligibility requirements, and time horizons. A compelling technology presented to the wrong audience or forced into the wrong program is unlikely to succeed.
Management teams should begin by clearly articulating the problem their innovation solves, why it matters now, the credibility of the underlying science, the team’s ability to execute, the milestone federal support will enable, and the path to the next stage of development once that support ends. The underlying facts may be familiar to the management teams, but the narrative must be translated from market opportunity into mission relevance and measurable public benefit.
3. Relationships and Coalitions Matter
Federal engagement is not an eleventh-hour application exercise. Building an informed network around the company can include relevant agency stakeholders, elected officials and their staff, patient or disease-focused organizations, research institutions, advocacy groups, and other aligned stakeholders. These relationships help educate decision-makers, demonstrate need, and create a stronger foundation before a specific funding or regulatory opportunity arises.
This does not need to be the exclusive domain of large-cap healthcare companies with extensive Washington resources. Small- and mid-cap companies can take a focused approach based on where they operate, conduct trials, employ people, manufacture products, and create economic or public-health value. For companies with activities across multiple states, those touchpoints may broaden the potential coalition.
4. Integrate The Teams That Shape Value
A federal strategy will be less effective if scientific, regulatory, finance, government affairs, communications and investor relations teams work independently. Each function holds part of the story. Together, they can identify the right opportunity, establish a realistic execution timeline, define the milestones that matter, and prepare to communicate progress appropriately.
This coordination is also essential for credibility. Government decision-makers need to understand the company’s ability to deliver a meaningful outcome. Investors need to understand how a federal award, regulatory designation or other milestone fits into the development plan, capital needs, and path to commercialization. The story should be consistent but calibrated for each audience.
5. Turn Progress into a Disciplined Investor Narrative
Federal funding and regulatory progress can provide meaningful external signals, but companies should avoid treating every interaction as promotional news. The investor-relations opportunity begins with a clear milestone framework: what uncertainty could be reduced, what evidence could be generated, what stage of development could be advanced and how the achievement may affect the company’s strategic position.
Once a milestone is reached and disclosure is appropriate, management should explain the development and its relevance in plain language. The goal is not merely to announce federal support; it is to help investors understand how that support advances the asset, contributes to de-risking and connects to the company’s broader capital and commercialization strategy.
The Next Practical Step
Healthcare companies should evaluate federal opportunities early in their broader financing and development strategy. A useful starting point is to map each priority asset against its stage of development, upcoming milestones, capital needs, alignment with relevant federal priorities, key stakeholder relationships, and communications considerations.
At Alliance Advisors IR, we help small- and mid-cap public and pre-IPO healthcare companies align corporate strategy, investor expectations, and capital-markets communications. In collaboration with Converge Public Strategies, we help management teams identify where federal engagement can advance strategic priorities, develop a coordinated roadmap, and translate progress into a clear, credible investment narrative.
Continue the conversation
To explore how we can support your company’s healthcare investor relations strategy, please contact Vivian Cervantes at vcervantes@allianceadvisors.com.